Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : 3PBiovian
Deal Size : Undisclosed
Deal Type : Collaboration
Eleva, 3PBIOVIAN Partner to Boost Capacity for Eleva’s Platform & Pipeline
Details : The collaboration aims to advance Factor H (CPV-104), a recombinant version of human complement Factor H, with a primary focus on delivering clinical data in C3 Glomerulopathy as the lead indication.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 04, 2025
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : 3PBiovian
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eleva Doses Factor H Therapy In C3-Glomerulopathy To Healthy Volunteers
Details : The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G).
Product Name : CPV-104
Product Type : Protein
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable